Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2018BloodOpen Access

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

View Full Paper
Ask AI
Bookmark
Share

Authors

PFPasquale L. FedeleSWSimon N. WillisYLYang Liao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fedele et al. (2018) studied this question.

synapsesocial.com/papers/6a1f3752d09bc027e4833012https://doi.org/10.1182/blood-2018-05-850727
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma2004 · 393 citations
  2. 2Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma2016 · 1,449 citations
  3. 3PML mediates IFN-α–induced apoptosis in myeloma by regulating TRAIL induction2005 · 54 citations
  4. 4Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma2007 · 13 citations
  5. 5Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma2017 · 231 citations